Company intelligence / Profile preview

Neos Therapeutics

Grand Prairie, Texas, United Statesdnb.com ↗

Ownership: Private
Development stage: Commercial

Overview

Neos Therapeutics developed and commercialized several extended-release medications for ADHD using proprietary drug delivery technologies. Its lead products—Adzenys XR‑ODT, Adzenys ER, Cotempla XR‑ODT—are approved in the US. The company also developed generic Tussionex for cough/upper respiratory symptoms and advanced NT0502 to Phase I trials targeting chronic sialorrhea. In March 2021 it was acquired by Aytu BioScience.

Therapeutic areas: PulmonologyPsychiatryNeurology
Modalities: Small moleculesExtended-release formulations (XR)Orally disintegrating tablets (ODT)Liquid suspensions
Industry: Biotech

Drug pipeline

3 assets

amphetamine

Commercial

Indications: ADHD

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Neos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neos Therapeutics.

Explore the full profile